{"id":745495,"date":"2017-09-11T08:00:00","date_gmt":"2017-09-11T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\/"},"modified":"2025-11-07T01:26:16","modified_gmt":"2025-11-07T06:26:16","slug":"merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\/","title":{"rendered":"Merck Announces Findings from Phase 3 Study of KEYTRUDA\u00ae (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma"},"content":{"rendered":"<p class=\"bwalignc\">       First Presentation of KEYNOTE-040 Results at ESMO 2017 Congress     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced results of the phase 3 KEYNOTE-040 trial investigating<br \/>\n      KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab), the company\u2019s anti-PD-1 therapy,<br \/>\n      compared to standard treatment (methotrexate, docetaxel or cetuximab) in<br \/>\n      patients with recurrent or metastatic head and neck squamous cell<br \/>\n      carcinoma (HNSCC) with disease progression on or after<br \/>\n      platinum-containing chemotherapy. As previously disclosed, the study did<br \/>\n      not meet its pre-specified primary endpoint of overall survival (OS).<br \/>\n      The findings include updated survival data showing a 19 percent<br \/>\n      reduction in the risk of death over standard treatment in the<br \/>\n      intent-to-treat population (HR, 0.81 [95% CI, 0.66-0.99]; one sided p =<br \/>\n      0.0204), with pre-specified p-value required for statistical<br \/>\n      significance of 0.0175, and a median OS of 8.4 months with KEYTRUDA (95%<br \/>\n      CI, 6.5-9.4) compared to 7.1 months with standard treatment (95% CI,<br \/>\n      5.9-8.1). Complete results will be presented for the first time at the<br \/>\n      European Society for Medical Oncology (ESMO) 2017 Congress in Madrid,<br \/>\n      Spain, in an oral presentation today from 3:00 \u2013&nbsp;3:12 p.m. CEST<br \/>\n      (Location: Granada Auditorium) (Abstract #LBA45_PR).\n    <\/p>\n<p>\n      \u201cThese data, including progression-free survival and overall response<br \/>\n      rate, show the activity and efficacy of pembrolizumab in this disease,<br \/>\n      and are consistent with prior studies of pembrolizumab in recurrent head<br \/>\n      and neck squamous cell carcinoma,\u201d said Ezra Cohen, M.D., associate<br \/>\n      director for translational science, Moores Cancer Center and co-director<br \/>\n      of the San Diego Center for Precision Immunotherapy, University of<br \/>\n      California, San Diego. \u201cKEYNOTE-40 strengthens the rationale for further<br \/>\n      studies, and expansion into earlier lines of disease.\u201d\n    <\/p>\n<p>\n      With more than 20 trials, Merck currently has the largest<br \/>\n      immuno-oncology clinical development program in head and neck cancer and<br \/>\n      is advancing multiple registration-enabling studies investigating<br \/>\n      KEYTRUDA (pembrolizumab) as monotherapy and in combination with other<br \/>\n      cancer treatments \u2013 including KEYNOTE-048 and KEYNOTE-412.\n    <\/p>\n<p>\n      \u201cAlthough the primary efficacy analysis did not show a statistically<br \/>\n      significant improvement in overall survival, these data add to the<br \/>\n      evolving science for KEYTRUDA in head and neck cancer,\u201d said Dr. Jon<br \/>\n      Cheng, associate vice president, Merck Research Laboratories.\n    <\/p>\n<p>\n      <b>Data in Second-Line Treatment Setting, KEYNOTE-040 (Abstract<br \/>\n      #LBA45_PR)<\/b>\n    <\/p>\n<p>\n      KEYNOTE-040 is a randomized, multi-center, phase 3 study investigating<br \/>\n      KEYTRUDA as a monotherapy (n=247) versus standard treatment<br \/>\n      (methotrexate, docetaxel or cetuximab) (n=248) in patients with<br \/>\n      recurrent or metastatic HNSCC (additional details on the trial design<br \/>\n      are provided below).\n    <\/p>\n<p>\n      Data presented at ESMO are based on findings in the intent-to-treat<br \/>\n      population (n=495) and include analysis of efficacy endpoints based on<br \/>\n      PD-L1 expression using two measurements: PD-L1 CPS \u22651 (n=387) and PD-L1<br \/>\n      TPS \u226550% (n=129). More than a third of patients in the intent-to-treat<br \/>\n      population went on to receive subsequent therapy, including 11 of 84<br \/>\n      patients in the KEYTRUDA arm and 31 of 100 patients in the standard<br \/>\n      treatment arm who received subsequent treatment with an immune<br \/>\n      checkpoint inhibitor. Other subsequent treatments included chemotherapy,<br \/>\n      EGFR inhibitor, kinase inhibitor, other immunotherapy, and other<br \/>\n      treatments.\n    <\/p>\n<p>\n      Data show that in the intent-to-treat population, the median OS was 8.4<br \/>\n      months with KEYTRUDA (95% CI, 6.5-9.4) compared to 7.1 months with<br \/>\n      standard treatment (95% CI, 5.9-8.1) (HR, 0.81 [95% CI, 0.66-0.99]; one<br \/>\n      sided p = 0.0204); the 12-month OS rate was 37.3 percent with KEYTRUDA<br \/>\n      compared to 27.2 percent with standard treatment. Further analysis of<br \/>\n      the primary endpoint based on PD-L1 expression showed:\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        In patients with PD-L1 CPS \u22651, the median OS was 8.7 months with<br \/>\n        KEYTRUDA (95% CI, 6.9-11.4) and 7.1 months with standard treatment<br \/>\n        (95% CI, 5.7-8.6) (HR, 0.75 [95% CI, 0.59-0.95]; p = 0.0078); the<br \/>\n        12-month OS rate was 40.1 percent with KEYTRUDA compared to 26.7<br \/>\n        percent with standard treatment.\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        In patients with PD-L1 TPS \u226550%, the median OS was 11.6 months with<br \/>\n        KEYTRUDA (95% CI, 8.3-19.5) and 7.9 months with standard treatment<br \/>\n        (95% CI, 4.8-9.3) (HR, 0.54 [95% CI, 0.35-0.82]; p = 0.0017); the<br \/>\n        12-month OS rate was 46.6 percent with KEYTRUDA compared to 25.8<br \/>\n        percent with standard treatment.\n      <\/li>\n<\/ul>\n<p>\n      The overall response rate (ORR) in the intent-to-treat population was<br \/>\n      14.6 percent in the KEYTRUDA (pembrolizumab) arm compared to 10.1<br \/>\n      percent in the standard treatment arm (p = 0.0610). In patients with<br \/>\n      PD-L1 CPS \u22651, the ORR was 17.3 percent with KEYTRUDA compared to 9.9<br \/>\n      percent with standard treatment (p = 0.0171). In patients with PD-L1 TPS<br \/>\n      \u226550%, the ORR was 26.6 percent with KEYTRUDA compared to 9.2 percent<br \/>\n      with standard treatment (p = 0.0009).\n    <\/p>\n<p>\n      The median progression-free survival (PFS) was 2.1 months in the<br \/>\n      intent-to-treat population with KEYTRUDA (95% CI, 2.1-2.3) and 2.3<br \/>\n      months with standard treatment (95% CI, 2.1-2.8) (HR, 0.95 [95% CI,<br \/>\n      0.79-1.16]; p = 0.3037). In patients with PD-L1 CPS \u22651, the median PFS<br \/>\n      was 2.2 months with KEYTRUDA (95% CI, 2.1-3.0) and 2.3 months with<br \/>\n      standard treatment (95% CI, 2.1-3.3) (HR, 0.89 [95% CI, 0.72-1.11]; p =<br \/>\n      0.1526). In patients with PD-L1 TPS \u226550%, the median PFS was 3.5 months<br \/>\n      with KEYTRUDA (95% CI, 2.1-6.3) and 2.2 months with standard treatment<br \/>\n      (95% CI, 2.0-2.5) (HR, 0.58 [95% CI, 0.39-0.87]; p = 0.0034).\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA was consistent with that observed in<br \/>\n      previously reported studies. Treatment-related adverse events (TRAEs) of<br \/>\n      any grade occurred in 155 patients (63.0%) in the KEYTRUDA arm and 196<br \/>\n      patients (83.8%) in the standard treatment arm. Across any arm, TRAEs<br \/>\n      with incidence of 10 percent or more included hypothyroidism, fatigue,<br \/>\n      diarrhea, rash, asthenia, anemia, nausea, mucosal inflammation,<br \/>\n      stomatitis, decreased neutrophil count and alopecia. Immune-mediated<br \/>\n      adverse events, any grade, occurring in the KEYTRUDA arm were<br \/>\n      hypothyroidism, pneumonitis, infusion reactions, severe skin reactions,<br \/>\n      hyperthyroidism, colitis, Guillain-Barre syndrome and hepatitis.<br \/>\n      Discontinuation due to TRAEs occurred in 15 patients (6.1%) in the<br \/>\n      KEYTRUDA arm and 12 patients (5.1%) in the standard treatment arm.<br \/>\n      Deaths due to treatment-related adverse events occurred in four patients<br \/>\n      (1.6%) in the KEYTRUDA arm and two patients (0.9%) in the standard<br \/>\n      treatment arm.\n    <\/p>\n<p>\n      <b>About KEYNOTE-040<\/b>\n    <\/p>\n<p>\n      KEYNOTE-040 is a randomized, multi-center, pivotal phase 3 study<br \/>\n      investigating KEYTRUDA as a monotherapy versus standard treatment<br \/>\n      (methotrexate, docetaxel or cetuximab) for the treatment of recurrent or<br \/>\n      metastatic HNSCC. The primary endpoint is OS; secondary endpoints<br \/>\n      include PFS and ORR. The study, which opened in November 2014, enrolled<br \/>\n      495 patients to receive KEYTRUDA (200 mg fixed dose every three weeks)<br \/>\n      or investigator-choice chemotherapy (methotrexate [40 mg\/m<sup>2<\/sup><br \/>\n      on Days 1, 8, and 15 of each 3-week cycle], docetaxel [75 mg\/m<sup>2<\/sup><br \/>\n      on Day 1 of each 3-week cycle], or cetuximab [400 mg\/m<sup>2<\/sup><br \/>\n      loading dose on Day 1 and 250 mg\/m<sup>2<\/sup> IV on Days 8 and 15 of<br \/>\n      Cycle 1], followed by cetuximab [250 mg\/m<sup>2<\/sup> on Days 1, 8, and<br \/>\n      15 of each subsequent 3-week cycle]). Patients enrolled in the study had<br \/>\n      been previously treated with one to two platinum-containing systemic<br \/>\n      regimens.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (pembrolizumab) Injection<br \/>\n      100mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of<br \/>\n      the body\u2019s immune system to help detect and fight tumor cells. KEYTRUDA<br \/>\n      is a humanized monoclonal antibody that blocks the interaction between<br \/>\n      PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes<br \/>\n      which may affect both tumor cells and healthy cells.\n    <\/p>\n<p>\n      Studies of KEYTRUDA \u2013 from the largest immuno-oncology program in the<br \/>\n      industry with more than 550 trials \u2013 include a wide variety of cancers<br \/>\n      and treatment settings. The KEYTRUDA clinical program seeks to<br \/>\n      understand factors that predict a patient\u2019s likelihood of benefitting<br \/>\n      from treatment with KEYTRUDA, including the exploration of several<br \/>\n      different biomarkers across a broad range of tumors.\n    <\/p>\n<p>\n      <b>KEYTRUDA (pembrolizumab)<\/b> <b>Indications and Dosing<\/b>\n    <\/p>\n<p>\n      <i>Melanoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with unresectable or<br \/>\n      metastatic melanoma at a fixed dose of 200 mg every three weeks until<br \/>\n      disease progression or unacceptable toxicity.\n    <\/p>\n<p>\n      <i>Lung Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is indicated for the first-line treatment<br \/>\n      of patients with metastatic non-small cell lung cancer (NSCLC) whose<br \/>\n      tumors have high PD-L1 expression [tumor proportion score (TPS) \u226550%] as<br \/>\n      determined by an FDA-approved test, with no EGFR or ALK genomic tumor<br \/>\n      aberrations.\n    <\/p>\n<p>\n      KEYTRUDA, as a single agent, is also indicated for the treatment of<br \/>\n      patients with metastatic NSCLC whose tumors express PD-L1 (TPS \u22651%) as<br \/>\n      determined by an FDA-approved test, with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA, in combination with pemetrexed and carboplatin, is indicated<br \/>\n      for the first-line treatment of patients with metastatic nonsquamous<br \/>\n      NSCLC. This indication is approved under accelerated approval based on<br \/>\n      tumor response rate and progression-free survival. Continued approval<br \/>\n      for this indication may be contingent upon verification and description<br \/>\n      of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      In metastatic NSCLC, KEYTRUDA (pembrolizumab) is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression.\n    <\/p>\n<p>\n      When administering KEYTRUDA in combination with chemotherapy, KEYTRUDA<br \/>\n      should be administered prior to chemotherapy when given on the same day.<br \/>\n      See also the Prescribing Information for pemetrexed and carboplatin.\n    <\/p>\n<p>\n      <i>Head and Neck Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with recurrent or<br \/>\n      metastatic head and neck squamous cell carcinoma (HNSCC) with disease<br \/>\n      progression on or after platinum-containing chemotherapy. This<br \/>\n      indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. In HNSCC, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression, unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Classical Hodgkin Lymphoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with refractory classical Hodgkin lymphoma (cHL), or who have relapsed<br \/>\n      after three or more prior lines of therapy. This indication is approved<br \/>\n      under accelerated approval based on tumor response rate and durability<br \/>\n      of response. Continued approval for this indication may be contingent<br \/>\n      upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials. In adults with cHL, KEYTRUDA is administered at a<br \/>\n      fixed dose of 200 mg every three weeks until disease progression or<br \/>\n      unacceptable toxicity, or up to 24 months in patients without disease<br \/>\n      progression. In pediatric patients with cHL, KEYTRUDA is administered at<br \/>\n      a dose of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until<br \/>\n      disease progression or unacceptable toxicity, or up to 24 months in<br \/>\n      patients without disease progression.\n    <\/p>\n<p>\n      <i>Urothelial Carcinoma<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of patients with locally<br \/>\n      advanced or metastatic urothelial carcinoma who are not eligible for<br \/>\n      cisplatin-containing chemotherapy. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and duration of<br \/>\n      response. Continued approval for this indication may be contingent upon<br \/>\n      verification and description of clinical benefit in the confirmatory<br \/>\n      trials.\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is also indicated for the treatment of patients<br \/>\n      with locally advanced or metastatic urothelial carcinoma who have<br \/>\n      disease progression during or following platinum-containing chemotherapy<br \/>\n      or within 12 months of neoadjuvant or adjuvant treatment with<br \/>\n      platinum-containing chemotherapy.\n    <\/p>\n<p>\n      In locally advanced or metastatic urothelial carcinoma, KEYTRUDA is<br \/>\n      administered at a fixed dose of 200 mg every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <i>Microsatellite Instability-High (MSI-H) Cancer<\/i>\n    <\/p>\n<p>\n      KEYTRUDA is indicated for the treatment of adult and pediatric patients<br \/>\n      with unresectable or metastatic microsatellite instability-high (MSI-H)<br \/>\n      or mismatch repair deficient (dMMR)\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        solid tumors that have progressed following prior treatment and who<br \/>\n        have no satisfactory alternative treatment options, or\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        colorectal cancer that has progressed following treatment with<br \/>\n        fluoropyrimidine, oxaliplatin, and irinotecan.\n      <\/li>\n<\/ul>\n<p>\n      This indication is approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. Continued approval for this<br \/>\n      indication may be contingent upon verification and description of<br \/>\n      clinical benefit in the confirmatory trials. The safety and<br \/>\n      effectiveness of KEYTRUDA in pediatric patients with MSI-H central<br \/>\n      nervous system cancers have not been established.\n    <\/p>\n<p>\n      In adult patients with MSI-H cancer, KEYTRUDA is administered at a fixed<br \/>\n      dose of 200 mg every three weeks until disease progression, unacceptable<br \/>\n      toxicity, or up to 24 months in patients without disease progression. In<br \/>\n      pediatric patients with MSI-H cancer, KEYTRUDA is administered at a dose<br \/>\n      of 2 mg\/kg (up to a maximum of 200 mg) every three weeks until disease<br \/>\n      progression or unacceptable toxicity, or up to 24 months in patients<br \/>\n      without disease progression.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup>&nbsp;<b>(pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated pneumonitis, including fatal cases.<br \/>\n      Pneumonitis occurred in 94 (3.4%) of 2799 patients receiving KEYTRUDA,<br \/>\n      including Grade 1 (0.8%), 2 (1.3%), 3 (0.9%), 4 (0.3%), and 5 (0.1%)<br \/>\n      pneumonitis, and occurred more frequently in patients with a history of<br \/>\n      prior thoracic radiation (6.9%) compared to those without (2.9%).<br \/>\n      Monitor patients for signs and symptoms of pneumonitis. Evaluate<br \/>\n      suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      (pembrolizumab) for Grade 2; permanently discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 or recurrent Grade 2 pneumonitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated colitis. Colitis occurred in 48<br \/>\n      (1.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.4%), 3<br \/>\n      (1.1%), and 4 (&lt;0.1%) colitis. Monitor patients for signs and symptoms<br \/>\n      of colitis. Administer corticosteroids for Grade 2 or greater colitis.<br \/>\n      Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 colitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated hepatitis. Hepatitis occurred in 19<br \/>\n      (0.7%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.4%), and 4 (&lt;0.1%) hepatitis. Monitor patients for changes in liver<br \/>\n      function. Administer corticosteroids for Grade 2 or greater hepatitis<br \/>\n      and, based on severity of liver enzyme elevations, withhold or<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause hypophysitis. Hypophysitis occurred in 17 (0.6%) of<br \/>\n      2799 patients receiving KEYTRUDA, including Grade 2 (0.2%), 3 (0.3%),<br \/>\n      and 4 (&lt;0.1%) hypophysitis. Monitor patients for signs and symptoms of<br \/>\n      hypophysitis (including hypopituitarism and adrenal insufficiency).<br \/>\n      Administer corticosteroids and hormone replacement as clinically<br \/>\n      indicated. Withhold KEYTRUDA for Grade 2; withhold or discontinue for<br \/>\n      Grade 3 or 4 hypophysitis.\n    <\/p>\n<p>\n      KEYTRUDA can cause thyroid disorders, including hyperthyroidism,<br \/>\n      hypothyroidism, and thyroiditis. Hyperthyroidism occurred in 96 (3.4%)<br \/>\n      of 2799 patients receiving KEYTRUDA, including Grade 2 (0.8%) and 3<br \/>\n      (0.1%) hyperthyroidism. Hypothyroidism occurred in 237 (8.5%) of 2799<br \/>\n      patients receiving KEYTRUDA, including Grade 2 (6.2%) and 3 (0.1%)<br \/>\n      hypothyroidism. The incidence of new or worsening hypothyroidism was<br \/>\n      higher in patients with HNSCC, occurring in 28 (15%) of 192 patients<br \/>\n      with HNSCC, including Grade 3 (0.5%) hypothyroidism. Thyroiditis<br \/>\n      occurred in 16 (0.6%) of 2799 patients receiving KEYTRUDA, including<br \/>\n      Grade 2 (0.3%) thyroiditis. Monitor patients for changes in thyroid<br \/>\n      function (at the start of treatment, periodically during treatment, and<br \/>\n      as indicated based on clinical evaluation) and for clinical signs and<br \/>\n      symptoms of thyroid disorders. Administer replacement hormones for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade<br \/>\n      3 or 4 hyperthyroidism.\n    <\/p>\n<p>\n      KEYTRUDA can cause type 1 diabetes mellitus, including diabetic<br \/>\n      ketoacidosis, which have been reported in 6 (0.2%) of 2799 patients.<br \/>\n      Monitor patients for hyperglycemia or other signs and symptoms of<br \/>\n      diabetes. Administer insulin for type 1 diabetes, and withhold KEYTRUDA<br \/>\n      and administer antihyperglycemics in patients with severe hyperglycemia.\n    <\/p>\n<p>\n      KEYTRUDA can cause immune-mediated nephritis. Nephritis occurred in 9<br \/>\n      (0.3%) of 2799 patients receiving KEYTRUDA, including Grade 2 (0.1%), 3<br \/>\n      (0.1%), and 4 (&lt;0.1%) nephritis. Monitor patients for changes in renal<br \/>\n      function. Administer corticosteroids for Grade 2 or greater nephritis.<br \/>\n      Withhold KEYTRUDA for Grade 2; permanently discontinue KEYTRUDA for<br \/>\n      Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Immune-mediated rashes, including Stevens-Johnson syndrome (SJS), toxic<br \/>\n      epidermal necrolysis (TEN) (some cases with fatal outcome), exfoliative<br \/>\n      dermatitis, and bullous pemphigoid can occur. Monitor patients for<br \/>\n      suspected severe skin reactions and based on the severity of the adverse<br \/>\n      reaction, withhold or permanently discontinue KEYTRUDA (pembrolizumab)<br \/>\n      and administer corticosteroids. For signs and symptoms of SJS or TEN,<br \/>\n      withhold KEYTRUDA and refer the patient for specialized care for<br \/>\n      assessment and treatment. If SJS or TEN is confirmed, permanently<br \/>\n      discontinue KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA can cause other clinically important immune-mediated adverse<br \/>\n      reactions. These immune-mediated reactions may occur in any organ<br \/>\n      system. For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement to Grade 1 or less, initiate<br \/>\n      corticosteroid taper and continue to taper over at least 1 month. Based<br \/>\n      on limited data from clinical studies in patients whose immune-related<br \/>\n      adverse reactions could not be controlled with corticosteroid use,<br \/>\n      administration of other systemic immunosuppressants can be considered.<br \/>\n      Resume KEYTRUDA when the adverse reaction remains at Grade 1 or less<br \/>\n      following corticosteroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      Grade 3 immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      The following clinically significant immune-mediated adverse reactions<br \/>\n      occurred in less than 1% (unless otherwise indicated) of 2799 patients:<br \/>\n      arthritis (1.5%), uveitis, myositis, Guillain-Barr\u00e9 syndrome, myasthenia<br \/>\n      gravis, vasculitis, pancreatitis, hemolytic anemia, and partial seizures<br \/>\n      arising in a patient with inflammatory foci in brain parenchyma. In<br \/>\n      addition, myelitis and myocarditis were reported in other clinical<br \/>\n      trials, including classical Hodgkin lymphoma, and postmarketing use.\n    <\/p>\n<p>\n      Solid organ transplant rejection has been reported in postmarketing use<br \/>\n      of KEYTRUDA. Treatment with KEYTRUDA may increase the risk of rejection<br \/>\n      in solid organ transplant recipients. Consider the benefit of treatment<br \/>\n      with KEYTRUDA vs the risk of possible organ rejection in these patients.\n    <\/p>\n<p>\n      KEYTRUDA can cause severe or life-threatening infusion-related<br \/>\n      reactions, including hypersensitivity and anaphylaxis, which have been<br \/>\n      reported in 6 (0.2%) of 2799 patients. Monitor patients for signs and<br \/>\n      symptoms of infusion-related reactions, including rigors, chills,<br \/>\n      wheezing, pruritus, flushing, rash, hypotension, hypoxemia, and fever.<br \/>\n      For Grade 3 or 4 reactions, stop infusion and permanently discontinue<br \/>\n      KEYTRUDA.\n    <\/p>\n<p>\n      Immune-mediated complications, including fatal events, occurred in<br \/>\n      patients who underwent allogeneic hematopoietic stem cell<br \/>\n      transplantation (HSCT) after being treated with KEYTRUDA. Of 23 patients<br \/>\n      with cHL who proceeded to allogeneic HSCT after treatment with KEYTRUDA<br \/>\n      (pembrolizumab) on any trial, 6 patients (26%) developed<br \/>\n      graft-versus-host-disease (GVHD), one of which was fatal, and 2 patients<br \/>\n      (9%) developed severe hepatic veno-occlusive disease (VOD) after<br \/>\n      reduced-intensity conditioning, one of which was fatal. Cases of fatal<br \/>\n      hyperacute GVHD after allogeneic HSCT have also been reported in<br \/>\n      patients with lymphoma who received a PD-1 receptor\u2013blocking antibody<br \/>\n      before transplantation. These complications may occur despite<br \/>\n      intervening therapy between PD-1 blockade and allogeneic HSCT. Follow<br \/>\n      patients closely for early evidence of transplant-related complications<br \/>\n      such as hyperacute GVHD, severe (Grade 3 to 4) acute GVHD,<br \/>\n      steroid-requiring febrile syndrome, hepatic VOD, and other<br \/>\n      immune-mediated adverse reactions, and intervene promptly.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      In KEYNOTE-006, KEYTRUDA was discontinued due to adverse reactions in 9%<br \/>\n      of 555 patients with advanced melanoma; adverse reactions leading to<br \/>\n      discontinuation in more than one patient were colitis (1.4%), autoimmune<br \/>\n      hepatitis (0.7%), allergic reaction (0.4%), polyneuropathy (0.4%), and<br \/>\n      cardiac failure (0.4%). Adverse reactions leading to interruption of<br \/>\n      KEYTRUDA occurred in 21% of patients; the most common (\u22651%) was diarrhea<br \/>\n      (2.5%). The most common adverse reactions with KEYTRUDA vs ipilimumab<br \/>\n      were fatigue (28% vs 28%), diarrhea (26% with KEYTRUDA), rash (24% vs<br \/>\n      23%), and nausea (21% with KEYTRUDA). Corresponding incidence rates are<br \/>\n      listed for ipilimumab only for those adverse reactions that occurred at<br \/>\n      the same or lower rate than with KEYTRUDA.\n    <\/p>\n<p>\n      KEYTRUDA monotherapy was discontinued due to adverse reactions in 8% of<br \/>\n      682 patients with metastatic NSCLC. The most common adverse event<br \/>\n      resulting in permanent discontinuation of KEYTRUDA was pneumonitis<br \/>\n      (1.8%). Adverse reactions leading to interruption of KEYTRUDA occurred<br \/>\n      in 23% of patients; the most common (\u22651%) were diarrhea (1%), fatigue<br \/>\n      (1.3%), pneumonia (1%), liver enzyme elevation (1.2%), decreased<br \/>\n      appetite (1.3%), and pneumonitis (1%). The most common adverse reactions<br \/>\n      (occurring in at least 20% of patients and at a higher incidence than<br \/>\n      with docetaxel) were decreased appetite (25% vs 23%), dyspnea (23% vs<br \/>\n      20%), and nausea (20% vs 18%).\n    <\/p>\n<p>\n      When KEYTRUDA was administered in combination with carboplatin and<br \/>\n      pemetrexed (carbo\/pem), KEYTRUDA was discontinued in 10% of 59 patients.<br \/>\n      The most common adverse reaction resulting in discontinuation of<br \/>\n      KEYTRUDA (\u22652%) was acute kidney injury (3.4%). Adverse reactions leading<br \/>\n      to interruption of KEYTRUDA (pembrolizumab) occurred in 39% of patients;<br \/>\n      the most common (\u22652%) were fatigue (8%), neutrophil count decreased<br \/>\n      (8%), anemia (5%), dyspnea (3.4%), and pneumonitis (3.4%).The most<br \/>\n      common adverse reactions (\u226520%) with KEYTRUDA compared to carbo\/pem<br \/>\n      alone were fatigue (71% vs 50%), nausea (68% vs 56%), constipation (51%<br \/>\n      vs 37%), rash (42% vs 21%), vomiting (39% vs 27%), dyspnea (39% vs 21%),<br \/>\n      diarrhea (37% vs 23%), decreased appetite (31% vs 23%), headache (31% vs<br \/>\n      16%), cough (24% vs 18%), dizziness (24% vs 16%), insomnia (24% vs 15%),<br \/>\n      pruritus (24% vs 4.8%), peripheral edema (22% vs 18%), dysgeusia (20% vs<br \/>\n      11%), alopecia (20% vs 3.2%), upper respiratory tract infection (20% vs<br \/>\n      3.2%), and arthralgia (15% vs 24%). This study was not designed to<br \/>\n      demonstrate a statistically significant difference in adverse reaction<br \/>\n      rates for KEYTRUDA as compared to carbo\/pem alone for any specified<br \/>\n      adverse reaction.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 17% of 192<br \/>\n      patients with HNSCC. Serious adverse reactions occurred in 45% of<br \/>\n      patients. The most frequent serious adverse reactions reported in at<br \/>\n      least 2% of patients were pneumonia, dyspnea, confusional state,<br \/>\n      vomiting, pleural effusion, and respiratory failure. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue,<br \/>\n      decreased appetite, and dyspnea. Adverse reactions occurring in patients<br \/>\n      with HNSCC were generally similar to those occurring in patients with<br \/>\n      melanoma or NSCLC, with the exception of increased incidences of facial<br \/>\n      edema (10% all Grades; 2.1% Grades 3 or 4) and new or worsening<br \/>\n      hypothyroidism.\n    <\/p>\n<p>\n      KEYTRUDA was discontinued due to adverse reactions in 5% of 210 patients<br \/>\n      with cHL, and treatment was interrupted due to adverse reactions in 26%<br \/>\n      of patients. Fifteen percent (15%) of patients had an adverse reaction<br \/>\n      requiring systemic corticosteroid therapy. Serious adverse reactions<br \/>\n      occurred in 16% of patients. The most frequent serious adverse reactions<br \/>\n      (\u22651%) included pneumonia, pneumonitis, pyrexia, dyspnea, GVHD, and<br \/>\n      herpes zoster. Two patients died from causes other than disease<br \/>\n      progression; one from GVHD after subsequent allogeneic HSCT and one from<br \/>\n      septic shock. The most common adverse reactions (occurring in \u226520% of<br \/>\n      patients) were fatigue (26%), pyrexia (24%), cough (24%),<br \/>\n      musculoskeletal pain (21%), diarrhea (20%), and rash (20%).\n    <\/p>\n<p>\n      In KEYNOTE-052, KEYTRUDA was discontinued due to adverse reactions in<br \/>\n      11% of 370 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reactions (in\u226520% of patients) were<br \/>\n      fatigue (38%), musculoskeletal pain (24%), decreased appetite (22%),<br \/>\n      constipation (21%), rash (21%), and diarrhea (20%). Eighteen patients<br \/>\n      (5%) died from causes other than disease progression. Five patients<br \/>\n      (1.4%) who were treated with KEYTRUDA experienced sepsis which led to<br \/>\n      death, and 3 patients (0.8%) experienced pneumonia which led to death.<br \/>\n      Adverse reactions leading to interruption of KEYTRUDA (pembrolizumab)<br \/>\n      occurred in 22% of patients; the most common (\u22651%) were liver enzyme<br \/>\n      increase, diarrhea, urinary tract infection, acute kidney injury,<br \/>\n      fatigue, joint pain, and pneumonia. Serious adverse reactions occurred<br \/>\n      in 42% of patients, the most frequent (\u22652%) of which were urinary tract<br \/>\n      infection, hematuria, acute kidney injury, pneumonia, and urosepsis.\n    <\/p>\n<p>\n      In KEYNOTE-045, KEYTRUDA was discontinued due to adverse reactions in 8%<br \/>\n      of 266 patients with locally advanced or metastatic urothelial<br \/>\n      carcinoma. The most common adverse reaction resulting in permanent<br \/>\n      discontinuation of KEYTRUDA was pneumonitis (1.9%). Adverse reactions<br \/>\n      leading to interruption of KEYTRUDA occurred in 20% of patients; the<br \/>\n      most common (\u22651%) were urinary tract infection (1.5%), diarrhea (1.5%),<br \/>\n      and colitis (1.1%). The most common adverse reactions (20%) in patients<br \/>\n      who received KEYTRUDA vs those who received chemotherapy were fatigue<br \/>\n      (38% vs 56%), musculoskeletal pain (32% vs 27%), pruritus (23% vs 6%),<br \/>\n      decreased appetite (21% vs 21%), nausea (21% vs 29%), and rash (20% vs<br \/>\n      13%). Serious adverse reactions occurred in 39% of KEYTRUDA-treated<br \/>\n      patients, the most frequent (\u22652%) of which were urinary tract infection,<br \/>\n      pneumonia, anemia, and pneumonitis.\n    <\/p>\n<p>\n      There is limited experience in pediatric patients. Efficacy for<br \/>\n      pediatric patients was extrapolated from the results in the adult cHL<br \/>\n      population. In a study of 40 pediatric patients with advanced melanoma,<br \/>\n      PD-L1\u2013positive advanced, relapsed, or refractory solid tumors or<br \/>\n      lymphoma, patients were treated with KEYTRUDA for a median of 43 days<br \/>\n      (range 1-414 days), with 24 patients (60%) receiving treatment for 42<br \/>\n      days or more. The safety profile in pediatric patients was similar to<br \/>\n      that seen in adults treated with KEYTRUDA. Toxicities that occurred at a<br \/>\n      higher rate (\u226515% difference) in these patients when compared to adults<br \/>\n      under 65 years of age were fatigue (45%), vomiting (38%), abdominal pain<br \/>\n      (28%), hypertransaminasemia (28%), and hyponatremia (18%).\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck, helping people<br \/>\n      fight cancer is our passion and supporting accessibility to our cancer<br \/>\n      medicines is our commitment. Our focus is on pursuing research in<br \/>\n      immuno-oncology and we are accelerating every step in the journey \u2013 from<br \/>\n      lab to clinic \u2013 to potentially bring new hope to people with cancer.\n    <\/p>\n<p>\n      As part of our focus on cancer, Merck is committed to exploring the<br \/>\n      potential of immuno-oncology with one of the fastest-growing development<br \/>\n      programs in the industry. We are currently executing an expansive<br \/>\n      research program evaluating our anti-PD-1 therapy across more than 30<br \/>\n      tumor types. We also continue to strengthen our immuno-oncology<br \/>\n      portfolio through strategic acquisitions and are prioritizing the<br \/>\n      development of several promising immunotherapeutic candidates with the<br \/>\n      potential to improve the treatment of advanced cancers.\n    <\/p>\n<p>\n      For more information about our oncology clinical trials, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51681376&amp;newsitemid=20170911005592&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=d80354071c485d07fd98c48311963272\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world\u2019s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer\u2019s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51681376&amp;newsitemid=20170911005592&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=bd9988e0f04ebe9bb22bf90d13f62a54\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n<span class=\"bwuline\"><br \/>\n      <\/span>and&nbsp;connect with us on&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51681376&amp;newsitemid=20170911005592&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=cedecf2fd0406e5e58f54dfcebfe1425\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=51681376&amp;newsitemid=20170911005592&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=8351c2c4e241c3b98e6123a798e9f7b2\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=51681376&amp;newsitemid=20170911005592&amp;lan=en-US&amp;anchor=Instagram&amp;index=5&amp;md5=9d9797ce11f8220acf68de20225646af\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51681376&amp;newsitemid=20170911005592&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=82a94b9dddb99eb70ddc5f0cd4dfd6c1\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51681376&amp;newsitemid=20170911005592&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=7&amp;md5=4f0adf827a7b11b04aa841bd904e4f10\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2016 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov%2F&amp;esheet=51681376&amp;newsitemid=20170911005592&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=8&amp;md5=3f4538d44187da548e06c2857ada0105\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51681376&amp;newsitemid=20170911005592&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=9&amp;md5=ff7aa77c474e3f78bca4322e896c3ebc\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>&nbsp;and<\/b><br \/>\n<br \/>\n<b>Patient<br \/>\n      Information\/Medication Guide for KEYTRUDA at&nbsp;<\/b><br \/>\n<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51681376&amp;newsitemid=20170911005592&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=10&amp;md5=d5598847da442ae1194456021e183f82\" rel=\"nofollow\"><br \/>\n<b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20170911005592r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Elizabeth Sell,        267-305-3877<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Amy        Klug, 908-740-1898     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results of the phase 3 KEYNOTE-040 trial investigating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, compared to standard treatment (methotrexate, docetaxel or cetuximab) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. As previously disclosed, the study did not meet its pre-specified primary endpoint of overall survival (OS). The findings include updated survival data showing a 19 percent reduction in the risk of death over standard treatment in the intent-to-treat population (HR, 0.81 [95% CI, 0.66-0.99]; one sided p = 0.0204), with pre-specified p-value required for statistical significance of 0.0175, and a median OS of 8.4 months with KEYTRUDA (95% CI, 6.5-9.4) compared to 7.1 months with standard treatment (95% CI, 5.9-8.1). Complete results will be presented for the first<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745495","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Findings from Phase 3 Study of KEYTRUDA\u00ae (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Findings from Phase 3 Study of KEYTRUDA\u00ae (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results of the phase 3 KEYNOTE-040 trial investigating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, compared to standard treatment (methotrexate, docetaxel or cetuximab) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. As previously disclosed, the study did not meet its pre-specified primary endpoint of overall survival (OS). The findings include updated survival data showing a 19 percent reduction in the risk of death over standard treatment in the intent-to-treat population (HR, 0.81 [95% CI, 0.66-0.99]; one sided p = 0.0204), with pre-specified p-value required for statistical significance of 0.0175, and a median OS of 8.4 months with KEYTRUDA (95% CI, 6.5-9.4) compared to 7.1 months with standard treatment (95% CI, 5.9-8.1). Complete results will be presented for the first\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:26:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"22 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\\\/\",\"name\":\"Merck Announces Findings from Phase 3 Study of KEYTRUDA\u00ae (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2017-09-11T08:00:00+00:00\",\"dateModified\":\"2025-11-07T06:26:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Findings from Phase 3 Study of KEYTRUDA\u00ae (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Findings from Phase 3 Study of KEYTRUDA\u00ae (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Findings from Phase 3 Study of KEYTRUDA\u00ae (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results of the phase 3 KEYNOTE-040 trial investigating KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, compared to standard treatment (methotrexate, docetaxel or cetuximab) in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or after platinum-containing chemotherapy. As previously disclosed, the study did not meet its pre-specified primary endpoint of overall survival (OS). The findings include updated survival data showing a 19 percent reduction in the risk of death over standard treatment in the intent-to-treat population (HR, 0.81 [95% CI, 0.66-0.99]; one sided p = 0.0204), with pre-specified p-value required for statistical significance of 0.0175, and a median OS of 8.4 months with KEYTRUDA (95% CI, 6.5-9.4) compared to 7.1 months with standard treatment (95% CI, 5.9-8.1). Complete results will be presented for the first","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:26:16+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"22 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\/","name":"Merck Announces Findings from Phase 3 Study of KEYTRUDA\u00ae (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2017-09-11T08:00:00+00:00","dateModified":"2025-11-07T06:26:16+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-findings-from-phase-3-study-of-keytruda-pembrolizumab-compared-to-standard-of-care-in-patients-with-previously-treated-recurrent-or-metastatic-head-and-neck-squamous-cell-car\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Findings from Phase 3 Study of KEYTRUDA\u00ae (pembrolizumab), Compared to Standard of Care, in Patients with Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"a0ce9af0-f619-4955-8f27-949bbf6ea24a","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Findings-from-Phase-3-Study-of-KEYTRUDA-pembrolizumab-Compared-to-Standard-of-Care-in-Patients-with-Previously-Treate-GLP7M.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745495","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745495\/revisions"}],"predecessor-version":[{"id":3674852,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745495\/revisions\/3674852"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745495"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745495"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}